JAZZ Q4 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.2B+10.1% YoY

Gross Profit

$1.2B97.9% margin

Operating Income

$909M75.9% margin

Net Income

$203M17.0% margin

EPS (Diluted)

$3.34

QoQ Revenue Growth

+6.4%

Cash Flow

Operating Cash Flow

$363M

Free Cash Flow

$297M

Stock-Based Comp.

$200M

Balance Sheet

Total Assets

$11.7B

Total Liabilities

$7.3B

Stockholders' Equity

$4.3B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.1B	+10.1%
Gross Profit	$1.2B	$959M	+22.3%
Operating Income	$909M	$191M	+376.6%
Net Income	$203M	$191M	+6.5%

Revenue Segments

Xywav

$465M40%

Epidiolex/Epidyolex

$287M25%

Rylaze/Enrylaze

$108M9%

Zepzelca

$90M8%

Defitelio/Defibrotide

$59M5%

High Sodium AG Oxybate Product Royalty Revenue

$56M5%

Xyrem

$38M3%

Vyxeos

$35M3%

Ziihera

$9M1%

Other Products

$3M0%

Sativex

$2M0%

Geographic Segments

UNITED STATES

$1.1B90%

Europe

$88M7%

Other Countries

$33M3%